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Abstract The well-characterized enhancement of the cardiac 
Ca 2+ L-type current by protein kinase A (PKA) is not observed 
when the corresponding channel is expressed in Xenopus oocytes, 
possibly because it is fully phosphorylated in the basal state. 
However, the activity of the expressed channel is reduced by 
PKA inhibitors. Using this paradigm as an assay to search for 
PKA sites relevant to channel modulation, we have found that 
mutation of serine 1928 of the ~lC subunit to alanine abolishes 
the modulation of the expressed channel by PKA inhihitors. This 
effect was independent of the presence of the [~ subunit. 
Phosphorylation of serine 1928 of CtlC may mediate the 
modulatory effect of PKA on the cardiac voltage-dependent 
Ca 2+ channel. 
Key words: Calcium channel; Protein kinase A; Modulation; 
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1. Introduction 
In a vast variety of animal species, the activity of the L-type 
(dihydropyridine-sensitive) voltage-dependent Ca 2+ channels 
in the heart and skeletal muscle (SkM) is strongly enhanced 
by epinephrine and norepinephrine, mainly via the cAMP- 
PKA pathway [1-3]. It is widely believed that this modulation 
is due to phosphorylation f one of the subunits of the chan- 
nel, catalyzed by PKA [2], and there is good, though not 
conclusive, evidence for such a direct mechanism in the 
SkM Ca 2+ channel. Of the four subunits of this channel 
(~IS, ~2[~, ~1 and 7), two (0~lS and ]31) are substrates for 
PKA-catalyzed phosphorylation [4-6], and the channel activ- 
ity is enhanced by PKA in native cells and after reconstitution 
of purified channel subunits in artificial membranes [7-9]. 
In contrast o SkM, the evidence for modulation of the 
cardiac L-type Ca z+ channel by a direct phosphorylation f 
one of its subunits by PKA is highly controversial. The mini- 
mal composition of the cardiac L-type channel is probably 
(XlC + a2/6 + ~2 [10-13]. The main, cqc, subunit of the chan- 
nel purified from adult cardiac tissue is a poor substrate for 
PKA [14,15]. A functional demonstration f modulation by 
PKA of the cardiac Ca 2+ channel expressed in various cell 
types also proved difficult and often irreproducible. Several 
groups reported an enhancement by PKA of currents through 
cardiac Ca 2+ channels formed by the C~lc subunit alone in 
CHO and HEK293 cells, although in some cases this increase 
was rather small or required a previous exposure of the chan- 
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nel to PKA inhibitors [16-18]. However, others [19,20] could 
not reproduce these results. When expressed in Xenopus oo- 
cytes, channels composed of cardiac or neuronal ale or 
cqc + (x2/~ are insensitive to PKA or PKA-activating treat- 
ments [21-23]. An early report [24] that coexpression of the [3 
subunit with alC renders the expressed channel sensitive to 
PKA also could not be confirmed [21-23]. 
It has been proposed that the failure of PKA to enhance the 
current via the expressed Ca 2+ channel in Xenopus oocytes 
may be due to an abnormally high level of its basal phosphor- 
ylation [21,22], possibly because of a difference in the balance 
between phosphorylation a d dephosphorylation processes in 
the heart and in the expression systems. This assumption is
supported by the finding that PKA inhibitors reduce the Ca 2+ 
current via channels formed by C~lc alone or with some or all 
of the auxiliary subunits in CHO and HEK293 cells and in 
Xenopus oocytes [17,20-22], suggesting that Cqc is the main 
target for this modulation. There is little doubt that the ob- 
served decrease in Ca 2-- channel current is caused by dephos- 
phorylation of PKA sites due to the activity of endogenous 
protein phosphatases, because the peptide and proteins used 
to inhibit PKA in these experiments are highly specific toward 
PKA [21]. If the target sites for dephosphorylation arelocated 
in the ale subunit, their elimination should abolish the effect 
of PKA inhibitors. Indeed, as reported below, we find that 
mutation of a single serine residue, Ser-1928, located in the C- 
terminal part of the cqc subunit, renders the rabbit cardiac L- 
type Ca 2+ channel expressed in Xenopus oocytes insensitive to 
PKA inhibitors, independently of the presence of the 132A sub- 
unit. 
2. Materials and methods 
2.1. Oocyte preparation, RNA injection, and ale mutagenesis 
The maintenance and surgery of the frogs, preparation of oocytes, 
and RNA injection were performed as described elsewhere [25]. RNAs 
specific for the cardiac siC (GenBank accession number of cDNA: 
X15539), [t2a and the skeletal muscle ~2/8 subunits were synthesized 
in vitro using Asp-718-cleaved pCaH, NotI-cleaved pCaB2a nd Sail- 
cleaved pCaA2 as templates [12,26]. Capped al, a~/8 and 1~2A mRNAs 
were synthesized in vitro using SP6 (for cq and 0~2/~5) and T7 (for 1~2A) 
RNA polymerases, as described [25]. To study the ~xl + a2/~ combi- 
nation, 5 ng of each of the RNAs of alc and c~2/fi were injected, and 
the oocytes were incubated for 5-7 days before lectrophysiological 
measurements. To study the cq + c~2/~5 + 13 combination, 2.5 ng of 
each of the RNAs of alc, a2/~ and ~2h were injected, and the oocytes 
were incubated for 3-5 days. Mutations $533I, st1665, S1700A and 
S1928A (see Fig. 2A) were generated by the oligonucleotide-directed 
in vitro mutagenesis k t (Amersham). In the mutation st1665, a stop 
codon (TAA) was inserted at the nucleotide position 5184; the result- 
ing cDNA was predicted to encode an ale deletion mutant lacking all 
C-terminal amino acids residues starting from K1665. All C-terminal 
mutations were performed on a cassette created by excising a stretch 
of alc cDNA with BstEII and Asp-718, which was subsequently in-
serted between the corresponding restriction sites of pSupEx-RCK1 
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[27]. The mutation $533I was performed on a cassette created by 
excising a stretch of Cqc cDNA with MunI and EcoRI which was 
subsequently inserted between the corresponding restriction sites of 
pB1-ShH4 [28]. The oligonucleotides were (underlined nucleotides in- 
dicate the mutated residue): 5'TGGAAATTCATCCGCTACTGGY 
($533I), 5'CAAGAAGCGCTAAGAGCAAGG3' (st1665), 5'ACGG- 
GCCATCGCCGGAGACCT3' (S1700A), 5'GTCGAAGGGCT- 
GCCTTCCACCTGY (S1928A). The deletion mutant ANs8_I3 9 was 
created in two steps. First, a PCR procedure was used to produce a 
stretch of nucleotides between bases A60o and G20~5 (the latter lies 
within a unique StuI site), with a forward primer 5'CTCTGCC- 
TCATCGATAAGAACCCCATCCGGA3' (which introduced a ClaI 
site before the position corresponding to the amino acid residue 
K140), and a reverse primer 5'GACACGAAATAGGCCTGCAGY. 
The PCR product was digested with ClaI and StuI and subcloned into 
the cDNA of alc, replacing the original DNA stretch located between 
these sites. This procedure liminated amino acid residues 88 through 
139 from the alc protein. The presence of the designed mutations was 
confirmed by DNA sequencing as described [27]. 
2.2. Electrophysiological procedures and data analysis 
Whole cell currents were recorded using two-electrode voltage 
clamp with the Geneclamp 500 amplifier (Axon Instruments, Foster 
City, CA) as described [12], in a solution containing 40 mM Ba(OH)2, 
50 mM NaOH, 2 mM KOH and 5 mM HEPES, titrated to pH 7.5 
with methanesulfonic acid. Current-voltage (I-V) relations of the Ba 2+ 
current (IBm) were obtained by stepping the membrane potential from 
the holding potential (-80 mV) to various voltages in 10 mV steps. 
Leak currents were subtracted uring the analysis session. Data ac- 
quisition and analysis were done with pCLAMP (Axon Instruments). 
A full I-V relation was measured at least in 4 oocytes of each group 
and, except one experiment (effect of H89 on the channel composed of 
O~IC + U,2]8 + ~2A; Fig. 3B), each experiment was repeated at least in 
two different batches of oocytes. To enable comparison between var- 
ious batches, peak IB~ (measured at +20 mV) in each cell was ex- 
pressed as percent of the average peak current in the control group 
of the same oocyte batch, and the normalized currents were averaged 
across all batches. IBa in cells of the control groups was normalized in 
the same way, in order to obtain an estimate of variability of Isa in 
these groups. Averaged ata are presented as mean_+ S.E.M. When- 
ever two groups were compared, Student's t-test was used; for com- 
parison of many groups, non-parametric one-way ANOVA followed 
by Dunn's paired test was performed. 
2.3. Materials 
(Rp)-8-Bromoadenosine 3',5' cyclic monophosphorothioate (Rp- 
cAMPS) and H89 were from Biolog (Bremen, Germany). Rp-cAMPS 
was dissolved in water at 0.5 M and stored at -20°C. H89 was dis- 
solved in DMSO at 50 mM and stored at -20°C. The final concen- 
tration of DMSO in media used for the treatment of the cells with 
H89 was 0.1%; DMSO alone had no effect on IB~ at this concentra- 
tion. Materials for molecular biology were from Boehringer-Man- 
nheim and Promega. Other materials were from Sigma. 
3. Results 
In a previous work [21], we have shown that, in Xenopus 
oocytes, intracellular injection of protein phosphatase 1, or of 
specific peptide and protein inhibitors of PKA, reduces the 
current carried by Ba 2+ (IBa) via the rabbit cardiac L-type 
Ca 2+ channel of various subunit combinations by 30-40% at 
0 mV. This tedious and time-consuming procedure proved 
inefficient for the screening of a large amount of cells that 
was necessary in order to test a number of mutant ~1c chan- 
nels. Therefore, we have used a procedure in which groups of 
oocytes were incubated for 60-90 min in the absence (control) 
or in the presence of cell-permeable PKA inhibitors, Rp- 
cAMPS (0.5-1 mM) or H-89 (50 ~tM). An oocyte was then 
transferred to the regular high-Ba 2+ recording solution, and 
IBa was measured within 5 min. On the average, this treatment 
reduced the peak IBa (at +20 mV) through channels of 
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Fig. 1. Treatment by Rp-cAMPS reduces the Ba 2+ current via cardi- 
ac L-type Ca 2+ channels of ~1C+~21~ (A) or e(lC + %/8 + ~2A (B) 
composition. Upper panels show representative Ba2+ currents in oo- 
cytes of one batch, measured by voltage steps from -80 to +20 
mV. Lower panels show I-V curves averaged from control and Rp- 
cAMPS-treated oocytes of one batch (n = 6-9 oocytes in each 
group). 
O~ 1 + 0~2/~ or ctl + az/6 + ~ composition by about 20% (Fig. 
1). The extent of reduction was similar in channels of these 
two subunit combinations, in accord with our previous find- 
ings [21] (see Fig. 3A). The Rp-cAMPS treatment did not 
cause major changes in the voltage dependence of the Ba 2+ 
current (Fig. 1), although a slight (3-5 mV) shift to positive 
voltages was observed when normalized I-V curves were com- 
pared (not shown). Although the extent of reduction of IB~ 
was relatively small, it was reproducible in all oocyte batches. 
Note that, due to the shift in I-V curve, the Rp-cAMPS-in- 
duced inhibition was more pronounced at negative voltages. 
For  example, in the batch of oocytes shown in Fig. 1, in the 
al + et2/8 combination, the inhibition was 21% at +20 mV, 
but 35% at 0 mV, comparable to what was observed with 
intracellular injections. Unfortunately, in some of the mutant 
channels, the currents were too small to be reliably measured 
at 0 mV (see below), and the amplitudes of the Ba 2+ currents 
were always compared at +20 mV in the following. 
Rabbit cardiac alc protein contains 6 putative 'classical' 
PKA phosphorylation sites in the cytoplasmic domains [29]. 
These are S124 located in the N-terminal part, and several 
serines located in the C-terminal part at the positions 1575, 
1627, 1700, 1848, and 1928. In initial experiments, we ob- 
served no inhibition by Rp-cAMPS of IB~ via channels com- 
posed of c~z/8, I]2A, and a deletion mutant of alc, alc(st1665), 
that lacked all the C-terminal amino acid residues beyond 
1664 (data not shown), suggesting that a functionally impor- 
tant PKA site in txlc is located in the C terminus beyond this 
residue. The Ba 2+ currents via channels of the 
alc(st1665) + a2/5 composition were too small to be mea- 
sured reliably, and it was impossible to assess the extent of 
regulation of the mutant channel in the absence of the ~ sub- 
unit. We have then created a series of mutations of a lc  (Fig. 
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Fig. 2. Expression of cqc mutants in the oocytes. A: Schematic pre- 
sentation of the ale subunits and of the mutations made in it. B 
and C: Average amplitudes of Ba 2+ currents in WT and mutants 
channels composed of ale + a2/5 (B) and ale + a2/5 + 132A (C). 
Whole-cell Ba 2+ currents in these experiments were 729+70 nA 
(Oqc + a2/~), n = 46) and 2055 + 142 nA (Cqc + c~2/6 + 132A, n = 23) 
at +20 mV. The numbers above the bars indicate the numbers of 
cells tested. Asterisks indicate statistically significant differences 
(P < 0.05) obtained in two-tailed t-tests (C) or in a multiple group 
comparison (B) as described in section 2. 
2A), two of which (single site mutations $1700A and S1928A) 
eliminated prominent putative PKA phosphorylation sites 
from the C terminus, one (a AN88_139 deletion) eliminated 
an N-terminus PKA site (S124), and one (single site mutation 
$533I) eliminated a serine that is a putative protein kinase C 
(but not PKA) site. Channels containing the mutants 
alc(S1928A) and ~lc(AN88 139), in combination with a2/8, 
gave rise to whole-cell Ba 2+ currents that were significantly 
smaller than in control channels containing the wild type 
(WT) Cqc (Fig. 2B). A significantly smaller IB~ in channels 
containing the alc(S1928A) mutant was also observed in 
the presence of the [~2A subunit (Fig. 2C). 
The S1928A mutation completely eliminated the inhibitory 
effect of Rp-cAMPS on Is~ (Fig. 3A). In all other mutants, 
there were no significant differences in the extent of inhibition 
caused by Rp-cAMPS (Fig. 3A). Another PKA inhibitor, 
H89, which was somewhat more potent han Rp-cAMPS in 
reducing the WT IBm, also failed to reduce the current via 
channels containing the cqc(S1928A) mutant (Fig. 3B). The 
presence of the ~2A subunit did not affect the inhibition of IB~ 
by Rp-cAMPS or H89, and did not restore their effect on the 
channel containing the S1928A mutation (Fig. 3A,B). 
4. Discussion 
The main finding of this study is that the elimination of a 
single serine residue in the C-terminus of the pore-forming 
a~c subunit of the L-type Ca 2+ channel, serine 1928, sup- 
presses the ability of PKA inhibitors to modulate (reduce) 
the current. This strongly suggests that a direct phosphoryla- 
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tion by PKA of this amino acid residue is involved in mod- 
ulation of the channel's activity. Since our assay involved the 
measurement of effects of dephosphorylation (as a result of 
inhibition of the basal activity of PKA) rather than phosphor- 
ylation, it is not clear whether S1928 is the site whose phos- 
phorylation by PKA normally causes the Ca 2+ current in- 
crease in cardiac cells. However, if the hypothesis [17,21,22] 
that the inability of PKA to enhance the channel's activity is 
due to an abnormally high level of basal phosphorylation in 
expression systems i  correct, then there is a good chance that 
S1928 is indeed the functionally important site whose phos- 
phorylation by PKA underlies most of the adrenergic regula- 
tion of the cardiac Ca 2+ channel. It is noteworthy that chan- 
nels containing the alc(S1928A) mutant displayed a strongly 
reduced current amplitude. This is in line with the notion that 
the WT cqc expressed in the oocytes is normally highly phos- 
phorylated by PKA; alc(S1928A) cannot be phosphorylated 
and, therefore, conducts less current. 
Serine 1928 is conserved in neuronal and smooth muscle 
splice variants of ale [30 34]. It is unclear why the smooth 
muscle L-type Ca 2+ currents are not enhanced by PKA [35- 
38]. It may be hypothesized, by analogy with oocytes and 
CHO cells, that in smooth muscle cells the channel is fully 
phosphorylated; another possibility is that a majority of the 
channels contain a truncated cqc subunit hat, due a post- 
translational modification, loses a part of its C-terminus in- 
cluding the residue analogous to S1928. Posttranslational C- 
terminus truncation is well documented in the Cqs subunit of 
the skeletal muscle [5,39M1] and has been reported in the 
cardiac cqc protein [18]. Further studies will be needed to 
clarify this issue. However, C-terminal truncation of cqc can- 
not explain the lack of an enhancing effect of PKA on cardiac 
L-type Ca 2+ channels expressed in CHO cells and in Xenopus 
oocytes, for several reasons. (1) The alC protein in the plasma 
membrane of the oocytes and the membrane fraction of CHO 
cells is detected by a site-specific antibody directed against the 
very end of the C-terminus [42,43]. In both cases, a compar- 
able amount of alC was detected by a different antibody di- 
rected against an intracellular loop between repeats II and III, 
suggesting that most of the expressed protein was not trun- 
cated ([43]; T. Ivanina and N. Dascal, unpublished observa- 
tions). (2) The fact that mutation of S1928 to alanine has a 
robust effect on the channel modulation by PKA inhibitors 
suggests that, normally, this residue is present in a significant 
fraction of the functional WT channels. 
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Fig. 3. The effects of PKA inhibitors on Ba 2+ currents through WT 
and mutant cardiac Ca 2+ channels. Ordinate presents the decrease 
caused in peak IBa by 0.5 1 mM Rp-cAMPS (A) and 50 gM H89 
(B). Double asterisks (**) indicate statistically significant differences 
(P < 0.05) (A, left panel). A single asterisk (*) indicates P < 0.05 in 
a one-tailed but not a two-tailed t-test (A, right panel). 
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In light of our findings, it is interesting to compare the 
prominent PKA phosphorylation sites in cardiac cqc and 
the SkM alS. The major sites phosphorylated by PKA in 
the Cqs protein in vitro and in vivo are serines 1757 and 
1854 in the full-length form [5,44], and serine 687 in the C- 
terminal truncated form [4,44]. None of these residues are 
conserved in alC. Serine 1928 of cqc is not conserved in 
~ls. One implication of these differences i  that the molecular 
mechanisms of modulation of cardiac and skeletal muscle L- 
type Ca 2+ channels by PKA may be dissimilar, in spite of the 
homology in structure and the analogy in the physiological 
effects of this modulation. 
A cardiac 13 subunit is a substrate for PKA phosphorylation 
[15], and it has been proposed that the positive modulation of 
the cardiac L-type Ca 2+ channel may be due to phosphoryla- 
tion of this subunit [10,15]. The presence of 13 may be neces- 
sary for a voltage-dependent facilitation of Ca 2+ channel cur- 
rent which, in turn, may be modulated by PKA [22]. 
However, most studies in expression systems do not support 
a role for the I] subunit, since coexpression of 13 with alc does 
not restore the positive modulation of the channel by PKA in 
Xenopus oocytes and in CHO cells and does not significantly 
alter the reducing effects of PKA inhibitors [20-23]. Our find- 
ing that the removal of a single PKA site in ~lC completely 
eliminates the effects of PKA inhibitors, and that the presence 
of the ~2A subunit does not restore these effects, also argues 
against he involvement of the 13 subunit in PKA modulation 
in the expression systems. However, since it appears that the 
PKA phosphorylation~lephosphorylation equilibrium is dif- 
ferent (and possibly unique) in the heart cells, such a role for 
13 there cannot be excluded. 
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